HOXB-AS1 and plasma cell myeloma: For instance, HOXB-AS1, which might function as a carcinogen and a promising therapeutic biomarker for the clinical treatment of patients with multiple myeloma, GBM, and endometrial carcinoma patients, has been shown to regulate cancer cell proliferation, migration, and invasion (Klebanov et al., 2019; Obaid et al., 2021).